Advertisement
AMRN vs ANAB
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is AMRN is a Hold and ANAB is a StrongBuy.
AMRN in upward trend: price may ascend as a result of having broken its lower Bollinger Band on October 01, 2026
AMRN may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 31 of 38 cases where AMRN's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 82%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where AMRN's RSI Oscillator exited the oversold zone, 26 of 35 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 74%.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 20 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
The Moving Average Convergence Divergence (MACD) for AMRN just turned positive on October 22, 2026. Looking at past instances where AMRN's MACD turned positive, the stock continued to rise in 37 of 54 cases over the following month. The odds of a continued upward trend are 69%.
Following a +1.04% 3-day Advance, the price is estimated to grow further. Considering data from situations where AMRN advanced for three days, in 184 of 251 cases, the price rose further within the following month. The odds of a continued upward trend are 73%.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on September 18, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on AMRN as a result. In 70 of 85 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 82%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where AMRN declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 85%.
The Aroon Indicator for AMRN entered a downward trend on October 22, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 25 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 68 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.552) is normal, around the industry mean (-3.019). P/E Ratio (-9.667) is within average values for comparable stocks, (21.251). Projected Growth (PEG Ratio) (3.220) is also within normal values, averaging (5.738). Dividend Yield (0.000) settles around the average of (0.041) among similar stocks. P/S Ratio (1.554) is also within normal values, averaging (4.033).
The Tickeron Price Growth Rating for this company is 78 (best 1 - 100 worst), indicating slightly worse than average price growth. AMRN’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 92 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. AMRN’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 61, placing this stock worse than average.
ANAB's RSI Indicator ascending out of oversold territory
The RSI Indicator for ANAB moved out of oversold territory on October 14, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 21 similar instances when the indicator left oversold territory. In 18 of the 21 cases the stock moved higher. This puts the odds of a move higher at 86%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 48 of 60 cases where ANAB's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 80%.
The Momentum Indicator moved above the 0 level on October 21, 2026. You may want to consider a long position or call options on ANAB as a result. In 73 of 94 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 78%.
The Moving Average Convergence Divergence (MACD) for ANAB just turned positive on October 15, 2026. Looking at past instances where ANAB's MACD turned positive, the stock continued to rise in 42 of 53 cases over the following month. The odds of a continued upward trend are 79%.
Following a +5.88% 3-day Advance, the price is estimated to grow further. Considering data from situations where ANAB advanced for three days, in 223 of 283 cases, the price rose further within the following month. The odds of a continued upward trend are 79%.
ANAB may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ANAB declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 81%.
The Aroon Indicator for ANAB entered a downward trend on October 22, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 35 (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 38 (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock slightly better than average.
The Tickeron Price Growth Rating for this company is 49 (best 1 - 100 worst), indicating steady price growth. ANAB’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 93 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: ANAB's P/B Ratio (112.808) is very high in comparison to the industry average of (2.973). P/E Ratio (-47.157) is within average values for comparable stocks, (-1.705). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (128.121) among similar stocks. P/S Ratio (6.614) is also within normal values, averaging (438.009).
The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
AMRN | ANAB | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 3 | 5 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 68 Overvalued | 93 Overvalued | |
PROFIT vs RISK RATING 1..100 | 100 | 38 | |
SMR RATING 1..100 | 92 | 99 | |
PRICE GROWTH RATING 1..100 | 78 | 49 | |
P/E GROWTH RATING 1..100 | 25 | 35 | |
SEASONALITY SCORE 1..100 | n/a | 65 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
AMRN's Valuation (68) in the Pharmaceuticals Other industry is in the same range as ANAB (93) in the Biotechnology industry. This means that AMRN’s stock grew similarly to ANAB’s over the last 12 months.
ANAB's Profit vs Risk Rating (38) in the Biotechnology industry is somewhat better than the same rating for AMRN (100) in the Pharmaceuticals Other industry. This means that ANAB’s stock grew somewhat faster than AMRN’s over the last 12 months.
AMRN's SMR Rating (92) in the Pharmaceuticals Other industry is in the same range as ANAB (99) in the Biotechnology industry. This means that AMRN’s stock grew similarly to ANAB’s over the last 12 months.
ANAB's Price Growth Rating (49) in the Biotechnology industry is in the same range as AMRN (78) in the Pharmaceuticals Other industry. This means that ANAB’s stock grew similarly to AMRN’s over the last 12 months.
AMRN's P/E Growth Rating (25) in the Pharmaceuticals Other industry is in the same range as ANAB (35) in the Biotechnology industry. This means that AMRN’s stock grew similarly to ANAB’s over the last 12 months.
| AMRN | ANAB | |
|---|---|---|
| RSI ODDS (%) | 1 day ago 74% | 1 day ago 86% |
| Stochastic ODDS (%) | 1 day ago 79% | 1 day ago 80% |
| Momentum ODDS (%) | 3 days ago 82% | 1 day ago 78% |
| MACD ODDS (%) | 1 day ago 69% | 1 day ago 79% |
| TrendWeek ODDS (%) | 1 day ago 76% | 1 day ago 81% |
| TrendMonth ODDS (%) | 1 day ago 85% | 1 day ago 81% |
| Advances ODDS (%) | 1 day ago 73% | 1 day ago 79% |
| Declines ODDS (%) | 7 days ago 85% | 16 days ago 81% |
| BollingerBands ODDS (%) | 1 day ago 82% | 1 day ago 77% |
| Aroon ODDS (%) | 1 day ago 78% | 1 day ago 82% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
AMRN’s FA Score shows that 1 FA rating(s) are green while ANAB’s FA Score has 1 green FA rating(s).
- AMRN’s FA Score: 1 green, 4 red.
- ANAB’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
AMRN’s TA Score shows that 4 TA indicator(s) are bullish while ANAB’s TA Score has 6 bullish TA indicator(s).
- AMRN’s TA Score: 4 bullish, 4 bearish.
- ANAB’s TA Score: 6 bullish, 2 bearish.
Price Growth
AMRN (@Pharmaceuticals: Major) experienced а -0.86% price change this week, while ANAB (@Biotechnology) price change was +2.72% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was +0.73%. For the same industry, the average monthly price growth was -4.97%, and the average quarterly price growth was +5.45%.
The average weekly price growth across all stocks in the @Biotechnology industry was -1.10%. For the same industry, the average monthly price growth was -18.18%, and the average quarterly price growth was -15.20%.
Reported Earning Dates
AMRN is expected to report earnings on Nov 04, 2026.
ANAB is expected to report earnings on Nov 03, 2026.
Industries' Descriptions
@Pharmaceuticals: Major (+0.73% weekly)The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.
@Biotechnology (-1.10% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
Advertisement
AMRN and
Correlation & Price change
A.I.dvisor indicates that over the last year, AMRN has been loosely correlated with CNTB. These tickers have moved in lockstep 55% of the time. This A.I.-generated data suggests there is some statistical probability that if AMRN jumps, then CNTB could also see price increases.
| Ticker / NAME | Correlation To AMRN | 1D Price Change % | ||
|---|---|---|---|---|
| AMRN | 100% | +0.78% | ||
| CNTB - AMRN | 55% Loosely correlated | -4.51% | ||
| HRTX - AMRN | 44% Loosely correlated | -12.57% | ||
| MGNX - AMRN | 44% Loosely correlated | +1.11% | ||
| ALXO - AMRN | 43% Loosely correlated | +3.48% | ||
| ARWR - AMRN | 40% Loosely correlated | -0.82% | ||
More | ||||
ANAB and
Correlation & Price change
A.I.dvisor indicates that over the last year, ANAB has been loosely correlated with CLRB. These tickers have moved in lockstep 40% of the time. This A.I.-generated data suggests there is some statistical probability that if ANAB jumps, then CLRB could also see price increases.
| Ticker / NAME | Correlation To ANAB | 1D Price Change % | ||
|---|---|---|---|---|
| ANAB | 100% | +0.33% | ||
| CLRB - ANAB | 40% Loosely correlated | -8.59% | ||
| QTTB - ANAB | 38% Loosely correlated | +1.50% | ||
| AMRN - ANAB | 38% Loosely correlated | +0.78% | ||
| JBIO - ANAB | 36% Loosely correlated | -1.45% | ||
| ORKA - ANAB | 35% Loosely correlated | +1.54% | ||
More | ||||
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| ISUL | 19.20 | 1.19 | +6.61% |
| GraniteShares 2x Long ISRG Daily ETF (ISUL) | |||
| PDBC | 20.02 | 0.04 | +0.20% |
| Invesco Optimum Yield Diversified Commodity Strategy No K-1 ETF (PDBC) | |||
| HYXF | 44.91 | 0.05 | +0.11% |
| iShares ESG Advanced High Yield Corporate Bond ETF (HYXF) | |||
| SIXP | 34.56 | -0.24 | -0.69% |
| AllianzIM U.S. Equity 6 Month Buffer10 Mar/Sep ETF (SIXP) | |||
| NPFE | 28.35 | -0.32 | -1.12% |
| NPF Core Equity ETF (NPFE) | |||